Literature DB >> 6611514

Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice.

R E Heikkila, F S Cabbat, L Manzino, R C Duvoisin.   

Abstract

1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) causes a destruction of the nigrostriatal dopamine pathway in humans as well as in monkeys. However, it has been reported that MPTP is inert in several small animal species. We now report that MPTP, given to mice at 30 mg/kg intraperitoneally, causes severe and long-lasting depletions of dopamine and its major metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the neostriatum.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6611514     DOI： 10.1016/0028-3908(84)90170-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  15 in total

1.  Transplacental effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on brain dopaminergic neurons in the mouse. An immunohistochemical study.

Authors:  S Furune; K Miura; K Watanabe; S Nagao; H Takahashi; M Sakai; M Spatz; I Nagatsu
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

2.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Authors:  Giuseppa Mudò; Johanna Mäkelä; Valentina Di Liberto; Timofey V Tselykh; Melania Olivieri; Petteri Piepponen; Ove Eriksson; Annika Mälkiä; Alessandra Bonomo; Minna Kairisalo; Jose A Aguirre; Laura Korhonen; Natale Belluardo; Dan Lindholm
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

Review 3.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

4.  Metallothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice.

Authors:  P Rojas; C Ríos
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

5.  Acetylcholinesterase inhibition by 1-methyl-4-phenylpyridinium ion, a bioactivated metabolite of MPTP.

Authors:  L Y Zang; H P Misra
Journal:  Mol Cell Biochem       Date:  1993-09-22       Impact factor: 3.396

6.  Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

Authors:  Dhanasekaran Muralikrishnan; Manuchair Ebadi; Holly M Brown-Borg
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

7.  Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice.

Authors:  E Garcia; C Rios; J Sotelo
Journal:  Neurochem Res       Date:  1992-10       Impact factor: 3.996

8.  Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.

Authors:  Manuela Di Benedetto; Chiara Cavina; Claudio D'Addario; Giorgia Leoni; Sanzio Candeletti; Brian M Cox; Patrizia Romualdi
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

9.  Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine.

Authors:  W Mihatsch; H Russ; H Przuntek
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Effect of MPTP on Dopamine metabolism in Ames dwarf mice.

Authors:  Dhanasekaran Muralikrishnan; Manuchair Ebadi; Holly M Brown-Borg
Journal:  Neurochem Res       Date:  2002-06       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.